Trump’s Executive Order on Prescription Drug Costs Delivers a Win for Pharma Companies
The Trump administration aims to change the Medicare Drug Price Negotiation Program in a way that would delay when certain drugs can be selected for negotiation.
The Big 3 PBMs are Countersuing the FTC. Does Their Argument Have Any Teeth?
After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of anticompetitive rebating practices related to insulin, the defendants reversed roles and became plaintiffs. In November, they countersued the agency, arguing that its lawsuit is unconstitutional.
Tackling Rising Drug Costs and Growing Popularity of GLP-1’s
See how Quantum Health is providing the steps to help their members tackle the cost of specialty medications and other drugs.
Managing the Specialty Drug Cost Challenge: Is Your Pharmacy Benefits Strategy Ready for 2025?
What concrete strategies should employers pursue to control rising costs while ensuring the best member experience and clinical outcomes?
HealthJoy, Cost Plus Drugs Partner To Reduce Drug Costs for Employers
HealthJoy and Mark Cuban Cost Plus Drug Company have teamed up. Through the partnership, HealthJoy can now direct the employees of its clients to the drug company when it offers a cheaper option for generic drugs.
An Upcoming White House Decision May Jeopardize Americans’ Access to Life-Saving Drugs
The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns “copay accumulators,” which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.
19 Senators Urge HHS to Drop Appeal That Would Jeopardize Americans’ Access to Life-Saving Drugs
A bipartisan group of senators sent a letter to HHS asking it to rethink its appeal of a recent federal district court decision that limits the use of “copay accumulators" — which are programs insurers use to prevent medication copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.
Consultants: Help Define What’s Next In Healthcare Benefits
Help shape the future of healthcare benefits by sharing your insights.
One VC Firm’s 5 Healthcare Predictions for 2024
Executives at LRVHealth expect to see a continued focus on generative AI, increased enrollment in Medicare Advantage and more in 2024.
Which Drugs Are Driving Next Year’s 3.42% Increase in Hospital Pharmacy Spend?
Hospitals’ pharmacy spending is projected to rise by 3.42% next year, according to a new report. Specialty drugs, including Ozempic and Humira, as well as neurology medications are the primary drivers of this increase in pharmacy expenses.
Medical Expenses Will Rise by 7% Next Year, Report Predicts
New research predicts that healthcare costs will increase by 7% next year. The estimate is higher than the projected medical cost trends in 2022 and 2023 — which were 5.5% and 6.0%, respectively.
National Alliance of Healthcare Purchaser Coalitions Develops Playbook for Managing Drug Costs
The National Alliance of Healthcare Purchaser Coalitions released a playbook on Monday that outlines the key concerns employers have about pharmacy benefit management, and provides several recommendations for employers.
Changes in Nurse Staffing Answer Clinician Demands
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
CDC: 8.2% of Adults Not Taking Medications as Prescribed Due To Cost
A recent CDC report found that many Americans are not taking their prescription medications as directed to reduce costs. There are significant differences in Americans doing so based on gender, race and coverage.
Express Scripts Launches New Solutions To Advance Drug Price Transparency
Express Scripts released several new solutions last week that aim to improve drug price transparency, including a cap on out-of-pocket costs for prescription drugs for consumers. The news comes amid increasing scrutiny against pharmacy benefit managers.
Zócalo Health Teams Up with Mark Cuban’s Pharmacy to Increase Medication Access for Latino Patients
Zócalo Health, a virtual primary care provider designed for Latino patients, recently forged a collaboration with Mark Cuban's Cost Plus Drugs. Now all Zócalo patients have access to Cost Plus Drugs’ prescriptions, and the provider's community health workers have been trained to help walk patients through the process of obtaining medications through the pharmacy.
Medicare Drug Negotiation Is the Model for the Future of Drug Pricing, Abarca CEO Says
For the first time ever, CMS is preparing to negotiate prices for drugs paid for by Medicare. This has sparked a huge debate — will the creation of this taxpayer-funded drug negotiation infrastructure be a failed experiment, or will it become the standard for the future of drug pricing in this country? Jason Borschow, president and CEO of Abarca Health, says it's the latter.
What Will Value-Based Drug Pricing Look Like By 2030? Experts Share 4 Predictions
Panelists at a recent pharmacy conference were optimistic about the future of value-based drug contracting. For example, one said that healthcare will be close to establishing a value-based formulary by 2030, and another said that longitudinal patient tracking will become a more important part the drug pricing process.